Skip to content

Non-inferiority Prospective Randomized Controlled Trial of Low-Dose Vaginal Misoprostol versus Conventional Oral Regimen for Cervical Preparation in Surgical Abortion at 10-12 Weeks’ Gestation

Non-inferiority Prospective Randomized Controlled Trial of Low-Dose Vaginal Misoprostol versus Conventional Oral Regimen for Cervical Preparation in Surgical Abortion at 10-12 Weeks’ Gestation

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500108652
Enrollment
Unknown
Registered
2025-09-03
Start date
2025-09-11
Completion date
Unknown
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early induced abortion

Interventions

study group:Administer 25 µ g misoprostol vaginal tablets 1.5 hours before surgery
control group:Take 400 µ g misoprostol tablets orally 2.5 hours and 0.5 hours before surgery, respectively

Sponsors

Women’s Hospital, Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. 18 years old< = age< = 40 years old; 2. Confirmed intrauterine pregnancy, gestational age of 10-12 weeks, meeting the indications for abortion surgery; 3. No contraindications to abortion, planned to undergo forceps curettage to terminate pregnancy; 4. Voluntarily sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Allergic to prostaglandin drugs; 2.History of cervical surgery (such as cervical conization, cervical electrocautery, cervical laser, etc.); 3.Existence of cervical diseases (such as cervical incompetence, cervical fibroids, cervicitis, cervical precancerous lesions, etc.); 4.Have taken or received medications or treatments that may affect cervical dilation; 5.Accompanied by abnormal mental state or cognitive impairment, unable to cooperate with research; 6.Other situations deemed unsuitable for inclusion by researchers;

Design outcomes

Primary

MeasureTime frame
Effective rate of cervical dilation (8.5mm pass rate);

Secondary

MeasureTime frame
Cervical dilation diameter (the maximum diameter that the cervical dilation rod can pass through before surgery); Surgical operation time (from the insertion of the intrauterine probe to the end of su;

Countries

China

Contacts

Public ContactJiang Xiuxiu

Women’s Hospital, Zhejiang University School of Medicine

jiangxiuxiu0418@zju.edu.cn+86 571 8999 2057

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026